The pharmaceutical sector is drawing attention again as global market revenue is expected to reach $1.21 trillion in 2025, confirming its role as a leading industry thanks to ongoing advances in treatments and growing demand for specialty drugs.
In this setting, major companies are positioning themselves carefully as investors focus more on firms that combine scale with reliable dividends. AbbVie (ABBV), with a market cap of over $320 billion, has gained more than 24% year-to-date (YTD), outperforming the broader pharmaceutical industry and delivering strong returns.
